Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.76, read 2026-11-05
Ethical passes the values gate
Price354.00 USD
Fair value400.00
Ethical score86.5/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-30Read Accumulation330.53+7.1% to today ✓Markup gives way to Accumulation first Accumulation read since October
2026-10-28Read Markup341.41+3.7% to today ✓Accumulation gives way to Markup first Markup read since October
2026-10-25Read Accumulation341.41+3.7% to today ✓Markup gives way to Accumulation after an 11% rise in 2 weeks
2026-10-11Read Markup306.92+15.3% to today ✓Distribution gives way to Markup first Markup read since August
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Cencora holds its Accumulation at $354.00. Consolidating, no directional conviction, held for 55 days.
As held on the ledger · 2026-11-04
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 55 days
Price at the screen
$354.00
Valuation
24.54 trailing · 16.72 forward price to earnings
Values screen
PASS· score 86.5
Beta
0.58
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.00%
Below 33%
Interest-bearing debt is just 10.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
38.62%
Below 49%
Money owed to the company is 38.6% of assets, under the 49% limit.
Pass
Revenue purity
0.04%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Cencora clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 10%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when COR's ethical verdict changes
Today COR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 12% discount to our $400.00 fair value, weak competitive moat, 5.10% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 11.5% discount to the base estimate.
Where our models see it going: fair-value estimate $400.00, with a range of $326.11 to $543.52, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Pharma distributor offers margin of safety today
Every hospital ward and corner pharmacy needs a steady flow of medicines and supplies. Cencora moves those products across the United States and beyond. The shares sit at a 28 percent discount to our fair value while the ethical screen clears without issue.
Forward earnings trade at 15.5 times with revenue rising 4 percent a year. Return on equity reaches 107 percent even though net margins stay thin at 1 percent. A weak moat leaves room for competitors yet the valuation and ethical pass keep the name on the opportunity list.
Thin margins and limited pricing power remain real concerns in a sector that can face sudden regulatory shifts. Low growth also caps how far any rerating might run. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
COR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$340.50+0.8%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$337.84+2.1%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$330.84+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$330.84+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$330.84+0.1%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$324.35-5.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup · changed$341.41+0.0%Entry 10
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357.
2026-10-18Markup$341.41+11.2%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
